Janux Therapeutics, Inc. (JANX)
18.15
+0.33
(+1.85%)
USD |
NASDAQ |
Nov 04, 15:40
Janux Therapeutics Net Income (Quarterly) : -21.97M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -21.97M |
| March 31, 2026 | -24.36M |
| December 31, 2025 | -31.95M |
| September 30, 2025 | -24.31M |
| June 30, 2025 | -33.86M |
| March 31, 2025 | -23.51M |
| December 31, 2024 | -20.22M |
| September 30, 2024 | -28.06M |
| June 30, 2024 | -5.959M |
| March 31, 2024 | -14.76M |
| December 31, 2023 | -11.76M |
| September 30, 2023 | -11.57M |
| June 30, 2023 | -17.51M |
| Date | Value |
|---|---|
| March 31, 2023 | -17.46M |
| December 31, 2022 | -16.06M |
| September 30, 2022 | -16.70M |
| June 30, 2022 | -16.89M |
| March 31, 2022 | -13.41M |
| December 31, 2021 | -13.42M |
| September 30, 2021 | -10.77M |
| June 30, 2021 | -6.206M |
| March 31, 2021 | -2.284M |
| December 31, 2020 | -1.655M |
| September 30, 2020 | -1.256M |
| June 30, 2020 | -2.46M |
| March 31, 2020 | -1.413M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Iovance Biotherapeutics, Inc. | -47.32M |
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 10.27M |
| Total Expenses (Quarterly) | 32.24M |
| EPS Diluted (Quarterly) | -0.3491 |
| Enterprise Value | 138.49M |
| Gross Profit Margin (Quarterly) | 95.49% |
| Profit Margin (Quarterly) | -214.0% |
| Earnings Yield | -9.06% |
| Normalized Earnings Yield | -9.057 |